Relevant bibliographies by topics / Prevention liver cancer

Academic literature on the topic 'Prevention liver cancer'

Author: Grafiati
Published: 30 May 2022
Last updated: 31 May 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Prevention liver cancer.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Prevention liver cancer"

1

Guyton, Kathryn Z., and Thomas W. Kensler. "Prevention of liver cancer." Current Opinion in Oncology 9, no. 5 (September 1997): 492–96. http://dx.doi.org/10.1097/00001622-199709050-00016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Guyton, Kathryn Z., and Thomas W. Kensler. "Prevention of liver cancer." Current Oncology Reports 4, no. 6 (December 2002): 464–70. http://dx.doi.org/10.1007/s11912-002-0057-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Nishino, Hoyoku, Michiaki Murakoshi, and Yoshiko Satomi. "Health Promotion by Antioxidants." Functional Foods in Health and Disease 1, no. 12 (December 30, 2011): 574. http://dx.doi.org/10.31989/ffhd.v1i12.105.

Full text
Abstract:
Background: Various antioxidnats from daily foods are expected to prevent lifestyle-related diseases. For example, natural carotenoid beta-cryptoxanthin seems to be a promising antioxidant, and based upon epidemiological data it was shown to be a possible cancer preventing agent. For this reason, we chose to study beta-cryptoxanthin more extensively.Methods and Results: From the result of clinical trial using beta-cryptoxanthin-enriched Mandarin orange juice, it was proven to potentiate the preventive activity of multi-carotenoid mixture against liver cancer in the patients with chronic viral hepatitis-induced liver cirrhosis. Furthermore, beta-cryptoxanthin also has preventive activity against alcohol-induced gamma-GTP elevation, and obesity.Conclusion: An antioxidant beta -cryptoxanthin seems to be valuable for health promotion.Key words: beta-Cryptoxanthin, Health promotion, Liver cancer prevention, Prevention of alcohol-induced gamma-GTP elevation, Prevention of obesity.
APA, Harvard, Vancouver, ISO, and other styles
4

Kudo, Masatoshi. "Prevention of Recurrence of Liver Cancer." Nihon Naika Gakkai Zasshi 97, no. 7 (2008): 1681–89. http://dx.doi.org/10.2169/naika.97.1681.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Key, Timothy J., Arthur Schatzkin, Walter C. Willett, Naomi E. Allen, Elizabeth A. Spencer, and Ruth C. Travis. "Diet, nutrition and the prevention of cancer." Public Health Nutrition 7, no. 1a (February 2004): 187–200. http://dx.doi.org/10.1079/phn2003588.

Full text
Abstract:
AbstractObjective:To assess the epidemiological evidence on diet and cancer and make public health recommendations.Design:Review of published studies, concentrating on recent systematic reviews, meta-analyses and large prospective studies.Conclusions and recommendations:Overweight/obesity increases the risk for cancers of the oesophagus (adenocarcinoma), colorectum, breast (postmenopausal), endometrium and kidney; body weight should be maintained in the body mass index range of 18.5–25?kg/m2, and weight gain in adulthood avoided. Alcohol causes cancers of the oral cavity, pharynx, oesophagus and liver, and a small increase in the risk for breast cancer; if consumed, alcohol intake should not exceed 2?units/d. Aflatoxin in foods causes liver cancer, although its importance in the absence of hepatitis virus infections is not clear; exposure to aflatoxin in foods should be minimised. Chinese-style salted fish increases the risk for nasopharyngeal cancer, particularly if eaten during childhood, and should be eaten only in moderation. Fruits and vegetables probably reduce the risk for cancers of the oral cavity, oesophagus, stomach and colorectum, and diets should include at least 400?g/d of total fruits and vegetables. Preserved meat and red meat probably increase the risk for colorectal cancer; if eaten, consumption of these foods should be moderate. Salt preserved foods and high salt intake probably increase the risk for stomach cancer; overall consumption of salt preserved foods and salt should be moderate. Very hot drinks and foods probably increase the risk for cancers of the oral cavity, pharynx and oesophagus; drinks and foods should not be consumed when they are scalding hot. Physical activity, the main determinant of energy expenditure, reduces the risk for colorectal cancer and probably reduces the risk for breast cancer; regular physical activity should be taken.
APA, Harvard, Vancouver, ISO, and other styles
6

Nan, Yuemin, Xiaoyuan Xu, Yanhang Gao, Rongqi Wang, Wengang Li, Ming Yang, Lingdi Liu, et al. "Consensus on the secondary prevention of primary liver cancer." Hepatology International 15, no. 6 (November 30, 2021): 1289–300. http://dx.doi.org/10.1007/s12072-021-10259-7.

Full text
Abstract:
AbstractTo standardize the effective prevention, surveillance, and diagnosis of primary liver cancer, the Chinese Society of Hepatology, Chinese Medical Association, invited clinical experts and methodologists to develop the Consensus on the Secondary Prevention of Primary Liver Cancer, which was based on the clinical and scientific advances on hepatocellular carcinoma. The purpose is to provide a current basis for the prevention, surveillance, and early diagnosis of primary liver cancer in patients with chronic liver diseases.
APA, Harvard, Vancouver, ISO, and other styles
7

Zuckerman, Arie J. "Prevention of Primary Liver Cancer by Immunization." New England Journal of Medicine 336, no. 26 (June 26, 1997): 1906–7. http://dx.doi.org/10.1056/nejm199706263362610.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kensler, Thomas W., Geng-Sun Qian, Jian-Guo Chen, and John D. Groopman. "Translational strategies for cancer prevention in liver." Nature Reviews Cancer 3, no. 5 (May 2003): 321–29. http://dx.doi.org/10.1038/nrc1076.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ramprasath, Vanu Ramkumar, and Atif B. Awad. "Role of Phytosterols in Cancer Prevention and Treatment." Journal of AOAC INTERNATIONAL 98, no. 3 (May 1, 2015): 735–38. http://dx.doi.org/10.5740/jaoacint.sgeramprasath.

Full text
Abstract:
Abstract Plant sterols or phytosterols have been shown to be effective in improving blood lipid profile and thereby protective against cardiovascular disease. In addition to their cardioprotective effects, phytosterols have gained more insight for their protective effect against various forms of cancer. Phytosterols have been reported to alleviate cancers of breast, prostate, lung, liver, stomach and ovary. Reductions in growth of various cancer cells including liver, prostate and breast by phytosterols treatment have been demonstrated. Although exact mechanisms of phytosterols for their anticancer effects are not very well delineated, there have been several mechanisms proposed such as inhibition of carcinogen production, cancer cell growth and multiplication, invasion and metastasis and induction of cell cycle arrest and apoptosis. Other mechanisms including reduction of angiogenesis, invasion and adhesion of cancer cells and production of reactive oxygen species have also been suggested. However, cancer therapy using phytosterol formulations have yet to be designed, largely due to the gap in the literature with regards to mode of action. Furthermore, most of the studies on anticancer effects of phytosterols were conducted in vitro and animal studies and need to be confirmed in humans.
APA, Harvard, Vancouver, ISO, and other styles
10

Li, William W., Vincent W. Li, Michelle Hutnik, and Albert S. Chiou. "Tumor Angiogenesis as a Target for Dietary Cancer Prevention." Journal of Oncology 2012 (2012): 1–23. http://dx.doi.org/10.1155/2012/879623.

Full text
Abstract:
Between 2000 and 2050, the number of new cancer patients diagnosed annually is expected to double, with an accompanying increase in treatment costs of more than $80 billion over just the next decade. Efficacious strategies for cancer prevention will therefore be vital for improving patients' quality of life and reducing healthcare costs. Judah Folkman first proposed antiangiogenesis as a strategy for preventing dormant microtumors from progressing to invasive cancer. Although antiangiogenic drugs are now available for many advanced malignancies (colorectal, lung, breast, kidney, liver, brain, thyroid, neuroendocrine, multiple myeloma, myelodysplastic syndrome), cost and toxicity considerations preclude their broad use for cancer prevention. Potent antiangiogenic molecules have now been identified in dietary sources, suggesting that a rationally designed antiangiogenic diet could provide a safe, widely available, and novel strategy for preventing cancer. This paper presents the scientific, epidemiologic, and clinical evidence supporting the role of an antiangiogenic diet for cancer prevention.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Prevention liver cancer"

1

Farah, Yasser Abdulhamid Elskay, and L. O. Averyanova. "Technologies for prevention liver cancer in Egypt." Thesis, ХНУРЕ, 2019. http://openarchive.nure.ua/handle/document/8373.

Full text
Abstract:
Deaths from liver cancer are common, especially in East Asia and Pacific, South Asia, and parts of Sub-Saharan Africa, largely as a result of infection decades ago. Controlling the risk factors would not only reduce the incidence of liver cancer; it would also reduce the incidence of cirrhosis and its other complications. This paper will discuss the clinical implications of imaging in screening, diagnosis, staging, and follow-up of patients in liver malignancies.
APA, Harvard, Vancouver, ISO, and other styles
2

Bayoumy, Hassan, and L. O. Averyanova. "Actual problems of stroke disease cure in Egypt." Thesis, Харків, ХНУРЕ, 2019. http://openarchive.nure.ua/handle/document/8375.

Full text
Abstract:
The causes of stroke disease in Egypt are considered. The diagnosis of stroke is explained, and the used diagnostic instruments are studied. The prevention liver cancer is explained. The treatment of each of the causes of liver cancer is analyzed.
APA, Harvard, Vancouver, ISO, and other styles
3

Davies, Richard. "Effect of selective COX-2 inhibitors on hepatic progenitor cells and the pathologies of experimental hepatocarcinogenesis." University of Western Australia. School of Medicine and Pharmacology, 2007. http://theses.library.uwa.edu.au/adt-WU2007.0190.

Full text
Abstract:
[Truncated abstract] Hepatocellular carcinoma (HCC) is the major malignancy complicating chronic liver disease. New therapies for the prevention of HCC are required due to the limited success and high tumour recurrence rates of existing treatments. Emerging evidence suggests that HCC arise from the transformation of adult liver progenitor cells (LPCs), which have the capacity to differentiate into hepatocytes and biliary cells during liver regeneration. LPC activation precedes neoplasia in experimental hepatocarcinogenesis. LPCs share antigenic epitopes with HCCs, including α-fetoprotein (AFP) and M2- pyruvate kinase (M2PK). In animal models of hepatocarcinogenesis, attenuation of the LPC response reduces the incidence of HCC following prolonged liver injury via a tumour necrosis factor (TNF) dependent mechanism. As TNF is a pro-inflammatory cytokine, these data suggest that anti-inflammatory agents may be effective in inhibiting LPC activation and hepatocarcinogenesis. Cyclo-oxygenase-2 (COX-2) is an inducible enzyme that mediates the production of many prostaglandins during inflammation and carcinogenesis. Recent investigations show that the administration of selective COX-2 inhibitors (SC2Is) may reduce the incidence of a variety of tumours including breast, colon and skin. The broad aim of this thesis was to conduct a series of detailed studies on the effects of a SC2I on LPC activation and the hepatic pathologies associated with hepatocarcinogenesis in order to test the hypothesis that S2CIs may be a beneficial therapy that can reduce liver injury and pre-neoplastic changes in the choline-deficient, ethionine supplemented (CDE) murine model of hepatocarcinogenesis. Administration of a SC2I (SC-236) significantly inhibited a variety of hepatic cell populations that expand during the first month of the CDE mouse model of hepatocarcinogenesis (a choline deficient, ethionine supplemented diet). Numbers of M2PK-positive LPCs (which are more hepatocytic in morphology and are also COX-2 positive) and inflammatory cells were all significantly reduced by SC-236. In contrast, numbers of A6-positive LPCs (which are more biliary cell-like in morphology and do not express COX-2) were unchanged. ... In summary, these data suggest that COX-2 inhibitors such as SC-236 inhibit LPC activation and a variety of pre-neoplastic liver pathologies as a result of COX-2 dependent and independent mechanisms that may be mediated through inhibition of Akt phosphorylation and induction of apoptosis. Moreover, SC2Is may be useful as preventative treatment strategies for HCC in patients with chronic liver disease.
APA, Harvard, Vancouver, ISO, and other styles
4

Wang, Ning Michael, and 王宁. "The preventive and curative potential of berberine and coptis on humanhepatocellular carcinoma." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2012. http://hub.hku.hk/bib/B48079637.

Full text
Abstract:
 Hepatocellular carcinoma (HCC) is the primary cancer of liver. It is the fifth common malignant tumor in men while seventh common in women. Aetiology of HCC is complex; however, it is now believed that sustained chronic liver injury and fibrosis are critically involved in the development of HCC. Prevention and treatment of HCC is far from desirable and prognosis remains poor. Coptis is a Chinese herbal Medicine which has been used for more than thousands years for clearing heats, dampness and toxics. Recently, studies from our group reported the hepatoprotective effect of Coptis and its major active component, berberine, on acute liver injury and berberine was extensively studied for their anti-tumor effect. However, there’s no comprehensive investigation focusing on the preventive and curative potential of berberine on HCC. Hence, here we hypothesized Coptis and berberine exhibits both preventive and curative effects on HCC. The prevention of HCC by berberine and Coptis may rely on their effects on chronic liver damage and fibrosis, and the curative action may depend on their actions on the angiogenesis, tumor growth and invasion of HCC. Both in vitro cell models and in vivo animal system were used in our study and some molecular events were investigated. We found that berberine and Coptis could significantly attenuate the chronic liver injury and fibrosis by restoring the anti-oxidative enzyme SOD activity in CCl4-, bile duct ligation- and alcohol-induced liver injury and fibrosis model. Recovery of SOD activity prevents the hepatocytes from apoptosis by inhibiting the oxidative stress-induced Erk1/2 signaling activation. The prevention of berberine and Coptis on chronic liver injury and fibrosis may contribute to its preventive effect against HCC. Then we found that berberine (as representative to Coptis) could suppress the angiogenesis of HCC, in which berberine does not directly act on the blood vessel formation, but suppress the expression and secretion of pro-angiogenic factors VEGF in HCC cells, and Id-1 inhibition by berberine plays a central role in the suppression of HIF-1α/VEGF and NF-κB pathways. We also found that berberine could induce both apoptotic and autophagic cell death in HCC, and the mitochondria related-caspases activation confers the apoptosis while mTOR inhibition initiates autophagy in berberine treated- cells. We found that berberine could suppress the migration and invasion of HCC cells as well, and Rho-GTPases/ROCK signaling is the particular target in berberine’s anti-invasive action. Finally, to dig out some molecular events involved in berberine’s action on HCC, we studied critically the mechanism underlying berberine’s inhibition on Cyclin D1 in HCC. We found berberine may promote the IKKα-induced Cyclin D1 phosphorylation at T286, and this may initiate the ubiquitination-dependent proteasomal degradation of Cyclin D1 in berberine-treated HCC cells and contribute to berberine’s anti-HCC action. Critical clinical trials and OMICS techniques were planned to further our comprehensive study on Coptis and berberine’s effects on HCC. In all, we found that berberine targets on different stages and molecules and exerts preventive and curative potential against HCC. Our study sheds light on the clinical application of berberine in HCC treatment.
published_or_final_version
Chinese Medicine
Doctoral
Doctor of Philosophy
APA, Harvard, Vancouver, ISO, and other styles
5

Abel, Stefan. "Fatty acids as cancer preventive tools in the dietary modulation of altered lipid profiles associated with hepatocarcinogenesis." Thesis, University of the Western Cape, 2005. http://etd.uwc.ac.za/index.php?module=etd&amp.

Full text
Abstract:
This thesis consists of a brief description on cancer, carcinogenesis, the changes in the type and level of dietary fat available in our diets over time and association with the development of certain diseases. The main focus of this research was on omega 6 and omega 3 essential fatty acids (EFA) and their interaction with regards to carcinogenesis.
APA, Harvard, Vancouver, ISO, and other styles
6

Orgad, Shani. "The use of the internet in the lives of women with breast cancer : narrating and storytelling online and offline." Thesis, London School of Economics and Political Science (University of London), 2003. http://etheses.lse.ac.uk/43/.

Full text
Abstract:
This thesis explores the experience of breast cancer patients' online participation in relation to their illness. The research focuses on the work of narrating as the key process in patients' online communication. Empirically, it stems from the noticeable recent proliferation of breast cancer forums, particularly in online spaces. I argue that the production of a story and its telling online enables the patient to cope with a radically new situation in her life. The claim for the significance of breast cancer patients' online communication, particularly narrating, is located within the historical and cultural context of the illness. In examining the process of narrating and storytelling, I draw on sociological and psychoanalytical theories of narrative and storytelling, and sociological debates on issues of health and illness, everyday life and the nature of agency, social exchange, and the tension between the public and the private. The study is based on a phenomenological study that included twenty nine online (e-mail) and twelve face-toface interviews with breast cancer patients, and a textual analysis of related websites. It shows how the work of narrating is facilitated through the online space, highlighting it as a process that has significant consequences for their ability to cope with their illness. The thesis concludes with a self-reflexive account of the employment of narrating as a conceptual, analytical and methodological tool for the study of breast cancer patients' processes of online communication. It argues for the need to acknowledge the constraints that shape the online space, calling into doubt its supposed openness, borderlessness, fluidity and lack of structure. In particular, the discussion highlights the persistence of the cultural dimension of the online communication, questioning the extent to which the nature of online communication is global, as is often argued. The concluding chapter uses the empirical case to engage with the broader concern with the relationship between media, communication and agency. Key words: narrative; narrating; storytelling; Internet; online; offline; breast cancer; agency; interviews.
APA, Harvard, Vancouver, ISO, and other styles
7

Kant, Rajni, and 康竣磊. "Identification of small molecules/natural compounds for therapeutic/preventive uses in liver cancer." Thesis, 2016. http://ndltd.ncl.edu.tw/handle/2wnyeg.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Prevention liver cancer"

1

Colvin, Heather M. Hepatitis and liver cancer: A national strategy for prevention and control of hepatitis B and C. Edited by Institute of Medicine (U.S.). Committee on the Prevention and Control of Viral Hepatitis Infections, Institute of Medicine (U.S.). Board on Population Health and Public Health Practice, and National Academies Press (U.S.). Washington, DC: National Academies Press, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

S, Luxenberg Jay, and Better Health Foundation, eds. You can't live forever, you can live 10 years longer with better health: A practical guide to reducing your risk of dying early from heart disease, cancer, stroke, osteoporosis & accidents. San Francisco, Calif: Better Health Foundation & UCSF/Mount Zion, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

McKinnell, Robert Gilmore. The understanding, prevention and control of human cancer: The historic work and lives of Elizabeth Cavert Miller and James A. Miller. Leiden: Brill, 2016.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Okita, K., and M. Omata. Therapy for Viral Hepatitis and Prevention of Hepatocellular Carcinoma. Springer, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Bamia, Christina, Sherri Stuver, and Lorelei Mucci. Cancer of the Liver and Biliary Tract. Oxford University Press, 2018. http://dx.doi.org/10.1093/oso/9780190676827.003.0012.

Full text
Abstract:
Primary liver cancer is one of the most commonly occurring cancers globally, and is the second most common cause of cancer death worldwide. There are two major histologic forms of primary liver cancer: hepatocellular carcinoma (HCC) and cholangiocarcinoma. It is a rapidly and almost uniformly fatal disease, yet there is already sufficient knowledge about its major risk factors, many of which are modifiable, to make primary prevention effective. Primary liver cancer is one of the first common human cancer that was found to have an infectious etiology, with hepatitis B virus (HBV) and hepatitis C virus (HCV) for HCC, and parasitic liver flukes for cholangiocarcinoma. Obesity is emerging as an important risk factor, particularly in Western countries, where primary liver cancer rates appear to be increasing over time. A number of additional risk factors and potential preventive factors are considered in this chapter.
APA, Harvard, Vancouver, ISO, and other styles
6

1925-, Blumberg Baruch S., ed. Hepatitis B and the prevention of primary cancer of the liver: Selected publications of Baruch S. Blumberg. Singapore: World Scientific, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Blumberg, Baruch S. Hepatitis B and the Prevention of Primary Cancer of the Liver. WORLD SCIENTIFIC, 2000. http://dx.doi.org/10.1142/3550.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

S, Cappell Mitchell, ed. Screening, prevention, and treatment of esophageal, gastric, and hepatic malignancies. Philadelphia: Saunders, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Keshav, Satish, and Alexandra Kent. Prevention of gastrointestinal disease. Edited by Patrick Davey and David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0346.

Full text
Abstract:
Disease prevention is usually directed where there is considerable morbidity or mortality, and etiological factors that can be controlled, treated, or reduced. The greatest morbidity and mortality from gastrointestinal disease is related to infectious diarrhoea and gastrointestinal cancer, both of which can be prevented. Smoking has been closely associated with oesophageal, gastric, and liver cancer and also has a significant effect in inflammatory bowel disease. In addition, alcohol consumption and viral hepatitis are preventable causes of liver disease, liver failure, and hepatic cancer. This chapter addresses the prevention of gastrointestinal disease, focusing on alcohol, smoking, peptic ulcer disease, colorectal cancer, oesophageal adenocarcinoma, hepatitis B, hepatitis C, non-alcoholic fatty liver disease, and gastrointestinal infection.
APA, Harvard, Vancouver, ISO, and other styles
10

M, Colvin Heather, Mitchell Abigail E, Institute of Medicine (U.S.). Committee on the Prevention and Control of Viral Hepatitis Infections., Institute of Medicine (U.S.). Board on Population Health and Public Health Practice., and National Academies Press (U.S.), eds. Hepatitis and liver cancer: A national strategy for prevention and control of hepatitis B and C. Washington, DC: National Academies Press, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Prevention liver cancer"

1

Bruckner, Howard W. "Adjuvant Therapy for Prevention of Liver Metastases." In Liver Cancer, 285–93. Boston, MA: Springer US, 1985. http://dx.doi.org/10.1007/978-1-4613-2593-2_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Chandok, Natasha, and Paul Marotta. "Recurrence: Prevention and Management." In Primary Liver Cancer, 215–27. Totowa, NJ: Humana Press, 2012. http://dx.doi.org/10.1007/978-1-61779-863-4_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Dharel, Narayan, and Daryl T. Lau. "The Impact of Treating Chronic Liver Diseases on Hepatocellular Carcinoma Prevention." In Primary Liver Cancer, 229–46. Totowa, NJ: Humana Press, 2012. http://dx.doi.org/10.1007/978-1-61779-863-4_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Heidor, R., J. M. Affonso, T. P. Ong, and F. S. Moreno. "CHAPTER 18. Nutrition and Liver Cancer Prevention." In Nutrition and Cancer Prevention, 339–67. Cambridge: Royal Society of Chemistry, 2019. http://dx.doi.org/10.1039/9781788016506-00339.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Bourgeois, N., V. Lefebvre, J. Van de Stadt, M. Gelin, M.-O. Peny, C. Deprez, T. Velu, and M. Adler. "Neoplastic diseases after liver transplantation." In Cancer in Transplantation: Prevention and Treatment, 328. Dordrecht: Springer Netherlands, 1996. http://dx.doi.org/10.1007/978-94-009-0175-9_44.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Metzger, U. "Prevention of Liver Metastases of Colorectal Carcinoma." In Recent Results in Cancer Research, 29–34. Berlin, Heidelberg: Springer Berlin Heidelberg, 1986. http://dx.doi.org/10.1007/978-3-642-82635-1_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Taltavull, T. Casanovas, C. Baliellas, M. Sánchez Gili, A. Casanova, C. Benasco, J. Fabregat, A. Rafecas, et al. "«De Novo» Carcinoma after Liver Transplant (L.T.)." In Cancer in Transplantation: Prevention and Treatment, 329. Dordrecht: Springer Netherlands, 1996. http://dx.doi.org/10.1007/978-94-009-0175-9_45.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lachaux, A., M. Chambon, O. Boillot, C. Le Gall, I. Loras, I. Canterino, J. M. Pouillaude, D. Gille, L. David, and M. Hermier. "Transient Hyperphosphatasemia after Liver Transplantation in Infancy." In Cancer in Transplantation: Prevention and Treatment, 348. Dordrecht: Springer Netherlands, 1996. http://dx.doi.org/10.1007/978-94-009-0175-9_61.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Chang, Mei-Hwei. "Prevention of Hepatitis B Virus Infection and Liver Cancer." In Viruses and Human Cancer, 71–90. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-57362-1_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Chang, Mei-Hwei. "Prevention of Hepatitis B Virus Infection and Liver Cancer." In Viruses and Human Cancer, 75–95. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-38965-8_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Prevention liver cancer"

1

Chang, Mei-Hwei. "Abstract SY26-03: Screening and strategies for liver cancer prevention." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-sy26-03.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Lin, Steven, Hyunseung Kang, Phillip Aguilar, Elton Chan, Monica Jeong, William Thieu, and Frank Trinh. "Abstract B123: Stopping a silent killer in the underserved Asian community: A novel liver cancer prevention clinic." In Abstracts: Frontiers in Cancer Prevention Research 2008. American Association for Cancer Research, 2008. http://dx.doi.org/10.1158/1940-6207.prev-08-b123.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Groopman, John. "Abstract PL02-01: Global disparities and prevention strategies in liver cancer." In Abstracts: AACR International Conference on the Science of Cancer Health Disparities‐‐ Sep 18-Sep 21, 2011; Washington, DC. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1055-9965.disp-11-pl02-01.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lu, Wenyue, Lin Zhu, Safa Ibrahim, Kerry Traub, Ellen Kim, Ada Wong, Nathaly Rubio-Torio, et al. "Abstract PO-058: Increasing liver cancer prevention knowledge through a community-based education initiative to improve liver cancer prevention for underserved African, Asian, and Hispanic communities." In Abstracts: AACR Virtual Conference: 14th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; October 6-8, 2021. American Association for Cancer Research, 2022. http://dx.doi.org/10.1158/1538-7755.disp21-po-058.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Diehl, Anna Mae E. "Abstract PL02-03: Early detection and prevention of liver cancer: Leveraging lessons learned from liver repair." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-pl02-03.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Chen, David C. P. "The Use of IgY (Immunoglobulin Yolk) in Cancer Prevention Seen in Liver and Stomach Cancers." In 2021 IEEE 3rd Eurasia Conference on Biomedical Engineering, Healthcare and Sustainability (ECBIOS). IEEE, 2021. http://dx.doi.org/10.1109/ecbios51820.2021.9510511.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Yang, Baiyu, Jessica L. Petrick, Christian C. Abnet, Barry I. Graubard, Stephanie J. Weinstein, Satu Männistö, Demetrius Albanes, and Katherine A. McGlynn. "Abstract A13: Tooth loss, liver cancer incidence, and chronic liver disease mortality in the ATBC study." In Abstracts: AACR Special Conference: Improving Cancer Risk Prediction for Prevention and Early Detection; November 16-19, 2016; Orlando, FL. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7755.carisk16-a13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lynch, Shannon M., Daniel Wiese, Kristen Sorice, Minhhuyen Nguyen, Evelyn Gonzalez, and Kevin Henry. "Abstract PR13: Geospatial analytics and sensitivity/specificity assessments to inform liver cancer prevention." In Abstracts: Eleventh AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; November 2-5, 2018; New Orleans, LA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7755.disp18-pr13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Lai, Gabriel Y., Jian-Bing Wang, Stephanie J. Weinstein, Dominick Parisi, Ronald L. Horst, Philip R. Taylor, Katherine A. McGlynn, Satu Månnistö, Demetrius Albanes, and Neal D. Freedman. "Abstract A59: Serum 25-hydroxyvitamin D and risk of incident liver cancer and chronic liver disease mortality in Finnish men." In Abstracts: Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; Oct 27-30, 2013; National Harbor, MD. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1940-6215.prev-13-a59.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Thompson, Patricia A. "Abstract CN04-03: Stemming the rising tide of liver and esophageal cancer." In Abstracts: Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; Oct 27-30, 2013; National Harbor, MD. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1940-6215.prev-13-cn04-03.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Prevention liver cancer' for particular source types:
Journal articles Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography